Becky Mccall

The odds of having obesity in middle age are sixfold higher if both parents also had obesity in middle age, showed data that shed some light on the nature of intergenerational patterns of obesity in families.

Tirzepatide (Zepbound for weight loss; Mounjaro for type 2 diabetes; Eli Lilly) consistently reduced body weight regardless of pretreatment body mass index (BMI) and reduced body weight and waist circumference regardless of duration of overweight or obesity.

May 12 - 15, 2024 Venice, Italy Conference News Popular News from ECO 2023 'Staggering' Weight Loss With Tirzepatide

Data on the investigative, temporary gut liner, EndoBarrier, showed improvement in weight, A1c, fatty liver, and need for insulin, and the effect persisted for up to 2 years after its removal.

Researchers demonstrated the model's excellent performance, raising hopes that it can someday prove a valuable tool for reducing such events in hospitalized patients.

VENICE, ITALY — Personalized doses and slow tapering of semaglutide (Wegovy or Ozempic, Novo Nordisk) in patients who also follow a digital weight

VENICE, Italy — Four-year data from the SELECT cardiovascular outcomes trial show that the anti-obesity drug semaglutide (Wegovy) leads to clinically

Semaglutide remains effective for weight loss at 4 years in people with preexisting cardiovascular disease and overweight/obesity but without T2D and provides CV benefits regardless of weight.

VENICE, Italy — Obesity as defined by adiposity measures corresponds to a lower body mass index (BMI) cutoff (≥ 27) in men and women of middle age

VENICE, ITALY — Differences in how adipose tissue responds to insulin may account for why type 2 diabetes is more common in men than in women with obesity, according to newly presented data.